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patient’s daily setup error was calculated as corrected shift 
distance by orthogonal electronic portal imaging device 
(EPID) and the target point marker on the thermoplastic 
mask. Each patient’s average of daily setup error size of 
medial-lateral (x), anterior-posterior (y) and cranial-caudal 
(z) axes was compared with that of 21 HNC patients (non-
protheses group) who did not use custom-designed oral 
prostheses during the same period. The non-prostheses group 
( pharyngeal: 11; oral cavity: 3; larynx: 3; thyroid: 2; and 
salivary gland: 2; histologically, 15 SqCC, 4 adenocarcinomas, 
and 2 lymphomas) received total doses of 45 to 70.0 Gy 
(mean 60.4 Gy) in fractions of 1.8 to 2.0 Gy per day. 18 of 
these patients (excepting 1 adenocarcinoma and 2 
lymphomas) received concurrent chemotherapy.  
Results: All patients tolerated the treatment, although they 
experienced grade 2 to 3 microsites, dermatitis and 
leukocytopenia. The average daily setup error for each 
prostheses group patient was less than that for the non-
prostheses group ( (x); 0.8 mm vs. 1.4 mm, (y); 0.7 mm 
vs.1.0mm, and (z); 0.8 mm vs. 1.3mm, respectively). Mean of 
(x) error with oral prostheses patients showed a significant 
difference (p=0.03). In addition, 3D-displacement (mean of 
sum squares of x, y, z) of prostheses group patients was less 
than that of non-prostheses group (5.0 vs.9.5, p=0.01). 
Conclusions: Custom-designed oral prostheses are self-
wearable safe devices. Use of custom-designed oral 
prostheses in HNC patients can reduce unnecessary radiation 
to OAR, and also provide better daily setup. More detailed 
evaluation in a larger patient population is desired in the 
future. 
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Purpose/Objective: A prospective trial investigated 
feasibility of a three-phase adaptive radiotherapy scheme 
using 18F-FDG-PET-CT guided dose-painting-by-numbers 
(DPBN) IMRT for head-and-neck cancer. We previously 
reported feasibility and clinical results upto 3 months. We 
now report on long-term locoregional (LRC) and distant 
control, overall survival (OS) and late toxicity. 
Materials and Methods: Ten patients with squamous cell 
carcinoma of the head and neck received primary 
radio(chemo)therapy using DPBN. All patients received 3 
consecutive phases of 10 fractions for in total 6 weeks. 18F-
FDG-PET-CT guided DPBN was planned beteen 2.0 – 3.5 Gy 
per fraction to the GTV (fractions 1-10) and 2.0-2.5 Gy 
(fractions 11-30). The elective neck was treated at 2.0 
Gy/fraction (fractions 1-20). Repeated 18F-FDG-PET-CT after 
fractions 8 and 18 were used to plan phase 2 and 3, 
respectively. Concomitant cisplatin at days 1-22-43 at 100 
mg/m² was prescribed in 4 patients. All patients underwent 
multidisciplinary assessment of disease control and late 
toxicity at months 1-3-6-9-12-16-20-24-30-36 after 
treatment. We analysed local, regional and distant control 
and survival; for toxicity evaluation we analysed all grades of 
late dysphagia, xerostomia and mucosal integrity problems as 
well as any other grade ≥ 3 late toxicity at 6, 12, 24 and 36 
months.  
 
Results:  
 
Patient and tumor characteristics can be found in Table 1.  
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Median follow-up in living patients was 38 months. One 
patient was lost from follow-up after 24 months. One patient 
treated with radiochemotherapy for a cT4a cN2b M0 
hypopharyngeal primary tumor was diagnosed with 
locoregional recurrence at 6 months of follow-up and 
deceased 3 weeks later. Due to renal insufficiency, he only 
received one cycle of cisplatin 100 mg/m² at day 1 of C-ART-
DPBN. There were no other locoregional or distant 
recurrences. A single other patient died due to a second 
primary lung carcinoma at 30 months after C-ART-DPBN. 
Actuarial LRC was 100%, 90%, 90% and 90% after 6, 12, 24 and 
36 months, respectively. Actuarial OS was 100%, 90%, 90% 
and 79% at 6, 12, 24 and 36 months, respectively.  
All grade 0-3 late xerostomia, dysphagia and mucosal 
integrity is shown in Figure 1. Grade 4 trismus was seen in 1 
patient at month 6, and reduced to grade 3 thereafter. One 
patient had a persistent skin ulcer upto 1 year of follow-up 
(scored as grade 4 skin necrosis) resulting from complete 
response of an involved neck node invading the skin; 
thereafter the wound healed spontaneously. There was no 
other grade 4 and no grade 5 late toxicity.  
Conclusions: Continuous adaptive radiotherapy using DPBN 
has been shown to be feasible and resulted in excellent 
locoregional control, survival and late toxicity. A multicentre 
prospective randomised trial is currently recruiting patients 
and will compare C-ART-DPBN to standard non-adaptive 
radiotherapy for head and neck cancer.  
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Purpose/Objective: Osteoradionecrosis (ORN) of the 
mandible is a feared late complication of high dose 
radiotherapy (RT) for head and neck cancer. ORN is often 
precipitated by extraction of carious teeth from a heavily 
irradiated mandible. The threshold dose, below which ORN 
does not occur is controversial, but generally believed to be 
above 60Gy in 2Gy per fraction. Many centres extract teeth 
prior to RT commencement to prevent ORN. Dental 
assessment, extractions and subsequent mandibular healing 
often delays RT simulation and start. This delay may affect 
tumour control. To minimise delay, efforts should be made to 
quickly and accurately identify areas of mandible at risk and 
focus assessment on the associated teeth, or completely 
bypass dental assessment. The aim of this study is to validate 
the accuracy of a rapid and objective 3D model for 
mandibular dose estimation that can be generated prior to 
patient simulation for RT. 
Materials and Methods: Ten consecutive patients treated 
definitively for mucosal squamous cell carcinoma (SCC) of the 
upper aero-digestive tract, with disease within 15mm of the 
mandible, were identified. All patients were treated over 35 
fractions to a maximum dose of 70Gy and had bilateral nodal 
irradiation to 56Gy using volumetric modulated arc therapy 
(VMAT). A PTV of 63Gy (biologically 60Gy in 30 fractions) was 
planned for each patient, consisting of a 10mm isotropic 
margin from GTV to CTV, and a further 5mm to PTV. Pinnacle 
9.6, was used to generate the auto-contoured MANDIBLE and 
a 63Gy DOSE structure, from the delivered plan. This dataset 
was imported into MIM 6.0, along with the patient’s PET and 
corresponding CT scan in RT position. The ‘PET Edge’ tool 
was used to auto-contour all primary tumours and upper 
cervical lymph nodes. A 15mm isotropic expansion was 
applied to create 63Gy MIM. The PET/CT was fused to the RT 
planning CT by MIM 6.0 The volume of overlap from the 
actual 63Gy DOSE and MANDIBLE, and 63gy MIM and MANDIBLE 
were recorded and compared using the Dice similarity 
coefficient (DSC).  
Results: All patients had stage IVa SCC. Nine patients had 
primaries of the oropharynx and one of the supraglottic 
larynx. Eight patients were male. The mean DSC of mandible 
between 63Gy DOSE and 63Gy MIM was 0.72. Sensitivity, 
specificity, positive and negative predictive values of the 
63Gy MIM model were 0.64, 0.98, 0.86 and 0.95 respectively. 
The mean and median volume of mandible receiving ≥63Gy 
was 6.4cc and 5.3cc respectively. 
Conclusions: Accurate dose prediction can be achieved using 
auto-contours from pre-therapy 18-FDG PET scans. Three-
dimensional visual displays of high mandibular dose may be 
useful for oral health practitioners to decide whether to 
prophylactically extract teeth. The volume of mandible 
receiving more than 63Gy is low, and the negative predictive 
value of this model is high. This suggests that the need for 
extraction may be relatively uncommon in centres using 
modern RT techniques. 
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Purpose/Objective: To evaluate long-term outcome in 
locoregionally advanced nasopharyngeal carcinoma (NPC) 
treated with Intensity-Modulated Radiotherapy-Simultaneous 
Integrated Boost (IMRT-SIB) and concurrent 
chemoradiotherapy (CHRT) +/- neoadjuvant chemotherapy 
(CHT). 
Materials and Methods: All patients (pts) were treated with 
IMRT-SIB (step and shoot techinque) and +/- neoadjuvant CHT 
(cisplatin - 5-fluorouracile or docetaxel+cisplatin+ 5-
fluorouracil every 21 days for 2 cycles) + concurrent CHRT 
(weekly cisplatin or cisplatin + 5-fluorouracil every 21 days). 
Computerized optimization was performed with fusion of MRI 
and/or PET with treatment planning CT images to accurately 
delineate the gross tumor volume (GTV), which included the 
primary disease and nodes greater than 1 cm in diameter or 
nodes with necrotic centers. The treated volumes and the 
dose delivered were as follows: Clinical Target Volume (CTV) 
